University of Cincinnati researchers have found a potential new combination therapy for breast cancer that would integrate use of the body’s immune system with targeted treatment for a particular protein that advances cancer.
The study, published in the journal Cancer Research, a journal of the American Association for Cancer Research, provides data that could eventually lead to a new breast cancer therapy, says co-lead author Syn Kok Yeo, PhD, research instructor in the department of cancer biology and a member in the lab of Jun-Lin Guan, the Francis Brunning Professor and Cancer Biology Department Chair.
Guan is a corresponding author on the paper.
“Cancer immunotherapy uses a patient’s immune system against tumour cells,” Yeo says. “It has emerged as a crucial treatment strategy, resulting in stable outcomes for cancer patients. However, most breast cancers are not responsive to immunotherapy, and this remains a colossal hurdle.”
In this study, researchers found that targeting a protein called FIP200 could “overwrite” the nonresponsive nature of breast cancers to certain immunotherapies, called immune checkpoint inhibitors.
“Disruption of the protein’s functions in tumour cells could essentially turn ‘cold’, or nonresponsive, tumours into ‘hot’, or responsive, tumours, susceptible to immunotherapy,” Yeo says. “Tumours that didn’t have this protein contained more T-cells, which is indicative of an immunologically ‘hot’ tumour. When coupled with immune checkpoint inhibitors in animal models with breast cancer, improved outcomes were observed when the protein wasn’t present.
“These findings indicate that targeting FIP200 could create a ‘hot spot’ for immunotherapy within these tumours.”
These findings expand upon previous studies by Guan’s lab that identified a tumour-promoting role of the protein in breast cancer.
“While the function of this protein in a cell-recycling process was previously identified as a culprit in breast cancer growth and progression, targeting this function did not make the tumours susceptible to immunotherapy,” Yeo adds. “This would imply that the protein has many roles in the development of breast cancer and targeting all of them simultaneously could improve treatment outcomes.
“Future studies are needed to develop therapeutic agents against this protein, to be used in combination with immunotherapy. These findings form a foundation for future clinical trials involving drugs that target the protein in breast cancers.”
Source: University of Cincinnati